Cleveland BioLabs dives after BARDA ends negotiations to back radiation drug
This article was originally published in Scrip
Cleveland BioLabs (CBLI) had a rough ride on Wall Street on 23 January, with shares diving 44% in morning trading, after the company revealed the US Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Health and Human Services, had terminated the negotiations on the biotech's proposal for further development of its investigational acute radiation syndrome agent entolimod (CBLB502) as a medical countermeasure (MCM).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.